ERT Clinical Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Philadelphia PA United States (1972)

Organization Overview

First Clinical Trial
2008
NCT00668850
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

eResearchTechnology | eResearch Technology, Inc. | ERT: Clinical Trial Technology Solutions | ERT Healthcare Company

Active Ingredients

Drugs in Phase 3 Trials (9)

Key: ERT Clinical (8) Acquired (1)

bedaquiline (sirturo) (2 trials)

birch allergen (1 trial)

clofazimine (lamprene) (2 trials)

formoterol (foradil) (1 trial)

glycopyrronium (robinul) (1 trial)

insulin human (humulin) (1 trial)

linezolid (zyvox) (2 trials)

moxifloxacin (avelox) (5 trials)

pretomanid (2 trials)

Drugs in Phase 2 Trials (5)

Key: ERT Clinical (1) Acquired (4)

ibogaine (1 trial)

ix-01 (1 trial)

medi-8968 (1 trial)

np2 (1 trial)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (4)

Key: ERT Clinical (3) Acquired (1)

alxn1840 (1 trial)

biotin (1 trial)

tapinarof (Vtama) (1 trial)

trazodone (desyrel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 18